TY - JOUR AU - Zhou, Ming AU - Chen, Xiaoyuan AU - Zhang, Hong AU - Xia, Lin AU - Tong, Xin AU - Zou, Limin AU - Hao, Ruimin AU - Pan, Jianhong AU - Zhao, Xiao AU - Chen, Dongmei AU - Song, Yuanyuan AU - Qi, Yueli AU - Tang, Ling AU - Liu, Zhifang AU - Gao, Rong AU - Shi, Yuankai AU - Yang, Zhimin PY - 2019 DA - 2019/06/20 TI - China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy JO - Cancer Communications SP - 36 VL - 39 IS - 1 AB - On May 8, 2018, the China National Medical Products Administration (NMPA) approved anlotinib, an orally administered anti-angiogenesis inhibitor, for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who have progressed after treatment with two or more lines of prior systemic chemotherapy. SN - 2523-3548 UR - https://doi.org/10.1186/s40880-019-0383-7 DO - 10.1186/s40880-019-0383-7 ID - Zhou2019 ER -